2
-Abnormal blood biochemistry defined as 3 times that of the upper limit of the normal range -Hepatic insufficiency defined as total bilirubin > 2 mg/dL or serum albumin < 25 g/L -HbA1c > 9.0% -Hemoglobin < 10 g/dL -Hematocrit < 0.30 -Platelet count < 100,000 Presence of an active systemic or local cancer or tumor of any kind (with the exception of non-melanoma skin cancer) With active osteomyelitis of the study foot With severe rheumatoid arthritis (with more than 20 persistently inflamed joints, or below lower normal limit blood albumin level, or evidence of bone and cartilage damage on X-ray, or inflammation in tissues other than joints) and other collagen vascular diseases With active connective tissue disease Treatment with systemic corticosteroids (>15 mg/day), or current immunosuppressive agents Previous or current radiation therapy or likelihood to receive this therapy during study participation Pregnant or nursing subjects Known prior inability or unavailability to complete required study visits during study participation A psychiatric condition (e.g. suicidal ideation) or chronic alcohol or drug abuse problem, determined from the subject's medical history, which, in the opinion of the Investigator, may pose a threat to subject compliance Use of any investigational drug or therapy within 28 days prior to screening Any other factor which may, in the opinion of the Investigator, compromise participation and follow-up during this study Figure S1 . Venous leg ulcer healing from baseline through week 12 in a subject treated with ACT1 and standard of care (compression bandage therapy) as compared to a subject receiving standard of care alone.
